Page last updated: 2024-09-03

imatinib mesylate and Aggressive Systemic Mastocytosis

imatinib mesylate has been researched along with Aggressive Systemic Mastocytosis in 65 studies

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	43 (66.15)	29.6817
2010's	20 (30.77)	24.3611
2020's	2 (3.08)	2.80

Authors

Authors	Studies
Gotlib, J	2
Pardanani, A	5
Falchi, L; Verstovsek, S	1
Fang, K; Jia, QN; Liu, YH	1
Broderick, V; Cross, NCP; Hayden, PJ; Jeffers, M; Langabeer, SE; Waghorn, K	1
Duan, MH; Li, WQ; Zhang, L; Zhao, DD; Zhou, DB; Zhuang, JL	1
Calabrò, C; Gadaleta, CD; Laforgia, M; Marech, I; Nardulli, P; Ranieri, G	1
Agarwala, MK; Balasubramanian, P; George, R; Mathews, V; Nair, S; Thomas, M	1
Kovalszki, A; Weller, PF	1
Barra, FF; Costa, FF; de Melo Campos, P; Duarte, AS; Lorand-Metze, I; Machado-Neto, JA; Olalla Saad, ST; Rogers, HJ; Scopim-Ribeiro, R; Tabarroki, A; Tiu, RV; Traina, F; Vassalo, J; Visconte, V	1
Bata-Csörgő, Z; Bödör, C; Borbényi, Z; Demeter, J; Korom, I; Marton, I; Papp, G; Pósfai, É; Varga, E	1
Bueso-Ramos, CE; Huang, L; Jabbour, E; Kanagal-Shamanna, R; Konoplev, S; Medeiros, LJ; Miranda, RN; Thakral, B; Wang, SA	1
Ando, M; Hirayama, Y; Kohda, K; Konuma, Y; Obata, M; Sasagawa, Y; Shirao, S; Ueno, Y; Wada, Y	1
Cortes, JE; Kantarjian, HM; Luthra, R; Manshouri, T; Quintás-Cardama, A; Sever, M; Vega-Ruiz, A; Verstovsek, S	1
Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V	1
Butterfield, JH; Li, CY; Lim, KH; Pardanani, A; Tefferi, A	1
Sadahira, Y; Takeuchi, M; Tsuchiyama, J; Yoshida, C	1
Blatt, K; Böhm, A; Gleixner, KV; Herrmann, H; Pehamberger, H; Peter, B; Pickl, WF; Rabitsch, W; Schernthaner, GH; Schuch, K; Sonneck, K; Sperr, WR; Valent, P	1
Hever, A; Johnston, WH; Kujubu, DA; Moore, AE; Peng, S	1
Brandal, S; Carter, M; Kapur, R; Lee, YN; McDevitt, MA; Mendell, JT; Metcalfe, DD; Noel, P; Takemoto, CM; Wentzel, E	1
Akin, C; DeRemer, DL; Ustun, C	1
Horny, HP; Jung, AG; Lippert, U; Overbeck, T; Schön, MP; Sotlar, K	1
Bonkobara, M; Ishii, N; Ito, K; Kobayashi, M; Kuroki, S; Ono, K; Sasaki, Y; Sugisaki, O; Washizu, T; Yamada, O	1
Alvarez-Twose, I; Escribano, L; González, P; Jara-Acevedo, M; Matito, A; Mollejo, M; Morgado, JM; Orfao, A; Sánchez-Muñoz, L	1
Arock, M; Bieche, Y; Castéran, N; De Sepulveda, P; Dorgham, K; Dubreuil, P; Dy, M; Féger, F; Gorochov, G; Hermine, O; Kersual, J; Létard, S; Lortholary, O; Parizot, C; Ribadeau Dumas, A; Vidaud, M; Zermati, Y	1
Brockman, SR; Cools, J; Cross, NC; Dewald, GW; Flynn, HC; Gilliland, DG; Ketterling, RP; Li, CY; Pardanani, A; Paternoster, SF; Reeder, TL; Shearer, BM; Tefferi, A	1
Baxter, EJ; Cross, NC; Elliott, M; Li, CY; Pardanani, A; Reeder, T; Tefferi, A	1
Barete, S; Bonté, I; Casassus, P; de Gennes, C; Fain, O; Hermine, O; Lortholary, O; Marrache, F; Mémain, N	1
Pardanani, A; Tefferi, A	2
Tefferi, A	1
Elliott, MA; Li, CY; Pardanani, A; Tefferi, A	1
Krystal, GW	1
Akin, C; Fumo, G; Lipsky, PE; Metcalfe, DD; Neckers, L; Yavuz, AS	1
Bodenizza, C; Carella, AM; Falcone, A; Musto, P; Sanpaolo, G	1
Cools, J; Gilliland, G; Marynen, P; Stover, EH; Wlodarska, I	1
Bain, BJ	1
Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S	1
Callera, F; Chauffaille, Mde L	1
Kanz, L; Sökler, M	1
Barete, S; Casassus, P; Eclache, V; Fain, O; Hermine, O; Lorholary, O; Stirnemann, J	1
Duyster, J; Gorantla, SH; Kancha, RK; Lordick, F; Peschel, C; von Bubnoff, N	1
Agis, H; Horny, HP; Sotlar, K; Valent, P	1
Binder, T; Esterbauer, H; Florian, S; Haas, OA; Müllauer, L; Sillaber, C; Sperr, WR; Valent, P	1
Akin, C; Donker, M; Jiang, Y; Lee, FY; Luo, R; Shah, NP	1
Boveri, E; Chichino, G; Cilloni, D; Daniela, C; Emanuela, B; Enrico, G; Giovanni, M; Gottardi, E; Guido, C; Martinelli, G; Merante, S; Serena, M; Simona, S; Soverini, S	1
Droogendijk, HJ; Kluin-Nelemans, HJ; Oranje, AP; van Daele, PL; van de Loosdrecht, AA; van Doormaal, JJ	1
Akin, C; Cortes, J; Giles, FJ; Huynh, L; Kantarjian, H; Manley, P; Manshouri, T; Quintás-Cardama, A; Tefferi, A; Verstovsek, S	1
Bonkobara, M; Hikosaka, M; Isotani, M; Ono, K; Tamura, K; Washizu, T; Yagihara, H	1
Barbie, DA; Deangelo, DJ	1
Agis, H; Aichberger, KJ; Gleixner, KV; Gruze, A; Krauth, MT; Mayerhofer, M; Müllauer, L; Pickl, WF; Selzer, E; Sillaber, C; Valent, P; Wacheck, V	1
Bruyèrè, H; Dalal, BI; Forrest, DL; Horsman, DE	1
Hirota, S; Nakagomi, N	1
Borneo, J; Chan, RJ; Kapur, R; Munugalavadla, V; Sims, EC	1
Lasota, J	1
Alfonso, A; Botana, LM; Escribano, L; Löber, K	1
Garcia, D; Gollard, RP; Ruemmler-Fish, C	1
Baccarani, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G	1
Akin, C; Arthur, DC; Cools, J; Kocabas, C; Lahortiga, I; Lessin, LS; Maric, I; Marynen, P; Mentens, N; Metcalfe, DD; Noel, P; Robyn, J; Wilson, TM; Wlodarska, I	1

Reviews

18 review(s) available for imatinib mesylate and Aggressive Systemic Mastocytosis

Article	Year
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. Hematology. American Society of Hematology. Education Program, 2022, 12-09, Volume: 2022, Issue:1 Topics: Child; Eosinophilia; Humans; Imatinib Mesylate; Mastocytosis; Mastocytosis, Systemic; Myeloproliferative Disorders; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit	2022
Kit Mutations: New Insights and Diagnostic Value. Immunology and allergy clinics of North America, 2018, Volume: 38, Issue:3 Topics: Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin; Staurosporine	2018
An evaluation of masitinib for treating systemic mastocytosis. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:13 Topics: Benzamides; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles	2019
Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. American journal of hematology, 2013, Volume: 88, Issue:7 Topics: Adrenal Cortex Hormones; Adult; Benzamides; Bone Marrow; CD2 Antigens; Cladribine; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Mutation; Palliative Care; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Factors; Tryptases	2013
Eosinophilia in mast cell disease. Immunology and allergy clinics of North America, 2014, Volume: 34, Issue:2 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Cell Communication; Eosinophils; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Stem Cell Factor	2014
Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. American journal of hematology, 2015, Volume: 90, Issue:3 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; Bone Marrow; Cell Proliferation; Cladribine; Disease Management; Humans; Imatinib Mesylate; Interferon-alpha; Mast Cells; Mastocytosis, Systemic; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Factors; Severity of Illness Index; Tryptases	2015
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles	2011
[Treatment of systemic mastocytosis]. La Revue de medecine interne, 2003, Volume: 24, Issue:9 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; Cladribine; Cytarabine; Diphosphonates; Enzyme Inhibitors; Histamine H1 Antagonists; Humans; Imatinib Mesylate; Interferon-alpha; Mastocytosis, Systemic; Photochemotherapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2003
Clinical, genetic, and therapeutic insights into systemic mast cell disease. Current opinion in hematology, 2004, Volume: 11, Issue:1 Topics: Adult; Benzamides; Cladribine; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2004
Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leukemia research, 2004, Volume: 28 Suppl 1 Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mastocytosis, Systemic; Myeloproliferative Disorders; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines	2004
FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 3 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis, Systemic; Mice; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Oncogenes; Piperazines; Pyrimidines; Radiation Chimera; Receptor, Platelet-Derived Growth Factor alpha; Xenograft Model Antitumor Assays	2004
Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. International journal of hematology, 2004, Volume: 79, Issue:5 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; DNA Mutational Analysis; Eosinophilia; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2004
Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. American journal of hematology, 2004, Volume: 77, Issue:1 Topics: Benzamides; Cytogenetic Analysis; Diagnosis, Differential; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2004
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. American journal of hematology, 2004, Volume: 77, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2004
[Systemic mastocytosis]. Presse medicale (Paris, France : 1983), 2005, May-14, Volume: 34, Issue:9 Topics: Benzamides; Biomarkers; Bone and Bones; Cell Differentiation; Cell Division; Cladribine; Diphosphonates; Flushing; Histamine H1 Antagonists; Histamine Release; Imatinib Mesylate; Interferon-alpha; Leukotriene Antagonists; Mast Cells; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Serine Endopeptidases; Stem Cell Factor; Tachycardia; Tryptases	2005
Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta haematologica, 2005, Volume: 114, Issue:1 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Humans; Imatinib Mesylate; Interferon-alpha; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Interleukin-2; Serine Endopeptidases; Tryptases	2005
Systemic mastocytosis: current classification and novel therapeutic options. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:10 Topics: Benzamides; Drug Design; Enzyme Activation; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction	2006
Imatinib mesylate in the treatment of hematologic malignancies. Expert opinion on biological therapy, 2007, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Drug Resistance; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome	2007

Trials

3 trial(s) available for imatinib mesylate and Aggressive Systemic Mastocytosis

Article	Year
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia research, 2009, Volume: 33, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Middle Aged; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome	2009
Imatinib for systemic mast-cell disease. Lancet (London, England), 2003, Aug-16, Volume: 362, Issue:9383 Topics: Adult; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome	2003
Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer, 2006, Jul-15, Volume: 107, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Female; Humans; Imatinib Mesylate; Male; Mast Cells; Mastocytosis, Systemic; Methylhistamines; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombination, Genetic; Treatment Outcome	2006

Other Studies

44 other study(ies) available for imatinib mesylate and Aggressive Systemic Mastocytosis

Article	Year
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. American journal of hematology, 2023, Volume: 98, Issue:7 Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Mast Cells; Mastocytosis, Systemic; Risk Assessment	2023
Rare lesion in the uterine cervix with irregular vaginal bleeding. American journal of obstetrics and gynecology, 2019, Volume: 220, Issue:6 Topics: Adult; Antineoplastic Agents; Female; Gynecologic Surgical Procedures; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Mastocytosis, Systemic; Metrorrhagia; Uterine Cervical Neoplasms	2019
Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis. Leukemia research, 2019, Volume: 77 Topics: Aged; Female; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit	2019
Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib. Chinese medical journal, 2019, Aug-20, Volume: 132, Issue:16 Topics: Adult; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Proto-Oncogene Proteins c-kit	2019
Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. The Journal of dermatological treatment, 2013, Volume: 24, Issue:6 Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Urticaria Pigmentosa; Young Adult	2013
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia research, 2014, Volume: 38, Issue:10 Topics: Adult; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Dasatinib; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles; Young Adult	2014
Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:9 Topics: Adult; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quality of Life; Urticaria Pigmentosa	2015
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine, 2016, Volume: 95, Issue:41 Topics: Antineoplastic Agents; Biopsy; DNA Mutational Analysis; DNA, Neoplasm; Female; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Mutation; Proto-Oncogene Proteins c-kit; Young Adult	2016
Skin lesions and mast cells. Blood, 2008, Jul-01, Volume: 112, Issue:1 Topics: Adult; Benzamides; Humans; Imatinib Mesylate; Male; Mast Cells; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Urticaria Pigmentosa	2008
[Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2008, Oct-10, Volume: 97, Issue:10 Topics: Aged; Benzamides; Codon; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome	2008
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Veterinary immunology and immunopathology, 2009, Dec-15, Volume: 132, Issue:2-4 Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles	2009
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. American journal of hematology, 2009, Volume: 84, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Bone Marrow; Cladribine; Dioxygenases; DNA Mutational Analysis; DNA-Binding Proteins; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Janus Kinase 2; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Prednisone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult	2009
On being metachromatic: mystique and misunderstanding in mastocytosis. American journal of hematology, 2009, Volume: 84, Issue:12 Topics: Benzamides; Cell Shape; Cladribine; Cytoplasmic Granules; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Mast Cells; Mastocytosis, Systemic; Piperazines; Pyrimidines; Retrospective Studies; Staining and Labeling	2009
Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:22 Topics: Benzamides; Bone Marrow; Drug Resistance; Female; Humans; Imatinib Mesylate; Interferon-alpha; Mast Cells; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines	2009
In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Experimental hematology, 2010, Volume: 38, Issue:9 Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Line, Tumor; Cladribine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tryptases	2010
Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature. International urology and nephrology, 2012, Volume: 44, Issue:2 Topics: Acute Kidney Injury; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Fatal Outcome; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kidney; Mastocytosis, Systemic; Middle Aged; Oliguria; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2012
KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood, 2011, Mar-31, Volume: 117, Issue:13 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Cells, Cultured; Gene Expression Regulation; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; Microphthalmia-Associated Transcription Factor; MicroRNAs; NIH 3T3 Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Staurosporine	2011
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. American journal of hematology, 2011, Volume: 86, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles	2011
Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:1 Topics: Absorptiometry, Photon; Administration, Oral; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Middle Aged; Osteolysis; Piperazines; Pyrimidines; Risk Assessment; Severity of Illness Index; Treatment Outcome	2011
Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. Veterinary journal (London, England : 1997), 2012, Volume: 193, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Female; Imatinib Mesylate; Intestinal Neoplasms; Mastocytosis, Systemic; Phosphorylation; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome	2012
Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-20, Volume: 30, Issue:12 Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mastocytosis, Systemic; Piperazines; Pyrimidines; Rare Diseases; Severity of Illness Index; Treatment Outcome	2012
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene, 2003, Feb-06, Volume: 22, Issue:5 Topics: Antineoplastic Agents; Benzamides; Catalytic Domain; Cell Line; Enzyme Inhibitors; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship	2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 2003, Nov-01, Volume: 102, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Eosinophilia; Gene Rearrangement; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Predictive Value of Tests; Prospective Studies; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Treatment Outcome	2003
Treatment of systemic mast cell disease: beyond interferon. Leukemia research, 2004, Volume: 28, Issue:3 Topics: Antimetabolites; Benzamides; Cladribine; Drug Evaluation; Humans; Imatinib Mesylate; Interferon-alpha; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Pilot Projects; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2004
Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis. Leukemia, 2004, Volume: 18, Issue:5 Topics: Adult; Benzamides; Bone Marrow Cells; Eosinophilia; Humans; Imatinib Mesylate; Immunophenotyping; Male; Mast Cells; Mastocytosis, Systemic; Piperazines; Pyrimidines	2004
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood, 2004, Apr-15, Volume: 103, Issue:8 Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Bone Marrow; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; In Vitro Techniques; Mast Cells; Mastocytosis, Systemic; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2004
Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leukemia research, 2004, Volume: 28, Issue:4 Topics: Adult; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome	2004
Aggressive systemic mastocytosis: is there a role for trisomy 8? Leukemia research, 2005, Volume: 29, Issue:4 Topics: Adult; Benzamides; Chromosome Mapping; Chromosomes, Human, Pair 8; Fatal Outcome; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Splenomegaly; Trisomy	2005
[Systemic mastocytosis]. Deutsche medizinische Wochenschrift (1946), 2005, Mar-04, Volume: 130, Issue:9 Topics: Anti-Inflammatory Agents; Benzamides; Cladribine; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interferon-alpha; Male; Mastocytosis, Systemic; Middle Aged; Piperazines; Prednisolone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2005
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia, 2005, Volume: 19, Issue:9 Topics: Amino Acid Substitution; Animals; Apoptosis; Benzamides; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mice; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines	2005
Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. Leukemia research, 2005, Volume: 29, Issue:10 Topics: Adult; Benzamides; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2005
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leukemia research, 2006, Volume: 30, Issue:9 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiomyopathies; Eosinophil Cationic Protein; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Serine Endopeptidases; Tryptases; World Health Organization	2006
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood, 2006, Jul-01, Volume: 108, Issue:1 Topics: Animals; Benzamides; Binding Sites; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Ligands; Mastocytosis, Systemic; Mice; Models, Molecular; Mutation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship; Thiazoles	2006
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Monomeric GTP-Binding Proteins; Piperazines; Polymorphism, Restriction Fragment Length; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction	2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leukemia research, 2006, Volume: 30, Issue:11 Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship	2006
Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Veterinary immunology and immunopathology, 2006, Nov-15, Volume: 114, Issue:1-2 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Cat Diseases; Cats; Exons; Germ-Line Mutation; Imatinib Mesylate; Male; Mastocytosis, Systemic; Molecular Sequence Data; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tandem Repeat Sequences	2006
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood, 2007, Apr-01, Volume: 109, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line; DNA Primers; Drug Synergism; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligoribonucleotides, Antisense; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Staurosporine; Transfection	2007
Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation. American journal of hematology, 2007, Volume: 82, Issue:1 Topics: Antineoplastic Agents; Benzamides; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Middle Aged; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Tumor Burden	2007
Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Laboratory investigation; a journal of technical methods and pathology, 2007, Volume: 87, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Cell Line; Humans; Imatinib Mesylate; Male; MAP Kinase Signaling System; Mastocytosis, Systemic; Mutation; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Transfection	2007
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood, 2007, Sep-01, Volume: 110, Issue:5 Topics: Amino Acid Substitution; Animals; Antibiotics, Antineoplastic; Benzamides; Cell Proliferation; Cell Transformation, Neoplastic; Cytokines; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematopoietic Stem Cells; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mice; Mice, Knockout; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Protein Subunits; Proto-Oncogene Proteins c-kit; Pyrimidines; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein; Sirolimus	2007
Not all c-kit mutations can be corrected by imatinib. Laboratory investigation; a journal of technical methods and pathology, 2007, Volume: 87, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction	2007
STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816. Journal of cellular biochemistry, 2008, Feb-15, Volume: 103, Issue:3 Topics: Acetophenones; Alkalies; Amine Oxidase (Copper-Containing); Apoptosis; Benzamides; Benzopyrans; Calcium; Cell Differentiation; Cell Line; Cell Proliferation; Cytoplasm; Drug Delivery Systems; Enzyme Inhibitors; Exocytosis; Histamine Release; Humans; Hydrogen-Ion Concentration; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction	2008
Systemic Mastocytosis: documented pathologic response to imatinib. European journal of haematology, 2007, Volume: 79, Issue:4 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Fatal Outcome; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Middle Aged; Piperazines; Pneumonia; Pyrimidines; Shock, Septic	2007
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica, 2008, Volume: 93, Issue:1 Topics: Animals; Benzamides; Bone Marrow; Cytogenetics; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Mice; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta	2008